LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase

Insup Choi1,2,3, Beomsue Kim2, Ji-Won Byun1,2

  • 1Department of Biomedical Sciences, Neuroscience Graduate Program, Ajou University School of Medicine, Suwon, Gyeonggi-do 443-380, Korea.

Nature Communications
|September 15, 2015
PubMed

Insights

Parkinson's disease mutations in the LRRK2 gene impair microglial cell motility and response to brain injury. This dysfunction may contribute to Parkinson's disease development by hindering protective brain mechanisms.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Genetics

Background:

  • Microglia are key immune cells in the brain, crucial for responding to injury.
  • The G2019S mutation in LRRK2 is a common cause of familial and sporadic Parkinson's disease.
  • LRRK2's role in microglial function and its link to Parkinson's disease pathology remain incompletely understood.

Purpose of the Study:

  • To investigate the impact of the G2019S-LRRK2 mutation on microglial cell function and response to brain injury.
  • To elucidate the molecular mechanisms by which LRRK2 affects microglial motility and injury response.

Main Methods:

  • Utilized G2019S-LRRK2 transgenic (GS-Tg) and LRRK2 knockdown microglia models.
  • Performed ADP-induced motility assays and lesion isolation experiments.
  • Investigated LRRK2 binding and phosphorylation of focal adhesion kinase (FAK) using biochemical assays and Western blotting for pY397 levels.

Main Results:

  • GS-Tg microglia exhibited reduced motility and delayed injury isolation compared to non-Tg microglia.
  • LRRK2 knockdown microglia demonstrated enhanced motility.
  • LRRK2 directly binds and phosphorylates FAK, attenuating its activity (decreased pY397).
  • GS-LRRK2 mutation reduced pY397 levels in brain, microglia, and HEK cells.
  • LRRK2 kinase inhibition restored pY397 levels and rescued microglial motility.

Conclusions:

  • The G2019S mutation in LRRK2 impairs microglial response to brain injury by inhibiting FAK signaling.
  • This impaired microglial function may represent a novel mechanism contributing to Parkinson's disease pathogenesis.
  • Targeting LRRK2 kinase activity could be a therapeutic strategy for Parkinson's disease.